Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene — Oct 2nd, 2024

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass., October 02, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in Eur...

Investing in Revvity (NYSE:RVTY) five years ago would have delivered you a 53% gain — Oct 7th, 2024

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the Revvity, Inc. (NYSE:RVTY) share price is up 51% in the last fiv...

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now — Oct 7th, 2024

Revvity, Inc. RVTY is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign excha...

Investing in Revvity (NYSE:RVTY) five years ago would have delivered you a 53% gain — Oct 7th, 2024

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the Revvity, Inc. (NYSE:RVTY) share price is up 51% in the last fiv...

Revvity To Hold Earnings Call on Monday, November 4, 2024 — Oct 7th, 2024

WALTHAM, Mass., October 07, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss the...

Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024

Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...

Investing in Revvity (NYSE:RVTY) five years ago would have delivered you a 53% gain — Oct 7th, 2024

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the Revvity, Inc. (NYSE:RVTY) share price is up 51% in the last fiv...

Revvity To Hold Earnings Call on Monday, November 4, 2024 — Oct 7th, 2024

WALTHAM, Mass., October 07, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss the...

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now — Oct 7th, 2024

Revvity, Inc. RVTY is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign excha...

Investing in Revvity (NYSE:RVTY) five years ago would have delivered you a 53% gain — Oct 7th, 2024

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the Revvity, Inc. (NYSE:RVTY) share price is up 51% in the last fiv...

Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024

Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...

Revvity To Hold Earnings Call on Monday, November 4, 2024 — Oct 7th, 2024

WALTHAM, Mass., October 07, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss the...

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now — Oct 7th, 2024

Revvity, Inc. RVTY is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign excha...

Revvity To Hold Earnings Call on Monday, November 4, 2024 — Oct 7th, 2024

WALTHAM, Mass., October 07, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss the...

Investing in Revvity (NYSE:RVTY) five years ago would have delivered you a 53% gain — Oct 7th, 2024

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the Revvity, Inc. (NYSE:RVTY) share price is up 51% in the last fiv...

Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024

Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...

Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024

Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...

Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene — Oct 2nd, 2024

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass., October 02, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in Eur...

Investing in Revvity (NYSE:RVTY) five years ago would have delivered you a 53% gain — Oct 7th, 2024

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the Revvity, Inc. (NYSE:RVTY) share price is up 51% in the last fiv...

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now — Oct 7th, 2024

Revvity, Inc. RVTY is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign excha...

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now — Oct 7th, 2024

Revvity, Inc. RVTY is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign excha...

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now — Oct 7th, 2024

Revvity, Inc. RVTY is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign excha...

Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024

Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...

Revvity To Hold Earnings Call on Monday, November 4, 2024 — Oct 7th, 2024

WALTHAM, Mass., October 07, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss the...

Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024

Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...

Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene — Oct 2nd, 2024

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass., October 02, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in Eur...

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now — Oct 7th, 2024

Revvity, Inc. RVTY is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign excha...

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now — Oct 7th, 2024

Revvity, Inc. RVTY is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign excha...

Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene — Oct 2nd, 2024

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass., October 02, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in Eur...

Revvity To Hold Earnings Call on Monday, November 4, 2024 — Oct 7th, 2024

WALTHAM, Mass., October 07, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss the...

Investing in Revvity (NYSE:RVTY) five years ago would have delivered you a 53% gain — Oct 7th, 2024

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the Revvity, Inc. (NYSE:RVTY) share price is up 51% in the last fiv...

Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene — Oct 2nd, 2024

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass., October 02, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in Eur...

Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene — Oct 2nd, 2024

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass., October 02, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in Eur...

Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024

Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...

Revvity To Hold Earnings Call on Monday, November 4, 2024 — Oct 7th, 2024

WALTHAM, Mass., October 07, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss the...

Investing in Revvity (NYSE:RVTY) five years ago would have delivered you a 53% gain — Oct 7th, 2024

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the Revvity, Inc. (NYSE:RVTY) share price is up 51% in the last fiv...

Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024

Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...

Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene — Oct 2nd, 2024

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass., October 02, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in Eur...

Revvity To Hold Earnings Call on Monday, November 4, 2024 — Oct 7th, 2024

WALTHAM, Mass., October 07, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss the...

Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene — Oct 2nd, 2024

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass., October 02, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in Eur...

Investing in Revvity (NYSE:RVTY) five years ago would have delivered you a 53% gain — Oct 7th, 2024

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the Revvity, Inc. (NYSE:RVTY) share price is up 51% in the last fiv...

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now — Oct 7th, 2024

Revvity, Inc. RVTY is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign excha...

Revvity To Hold Earnings Call on Monday, November 4, 2024 — Oct 7th, 2024

WALTHAM, Mass., October 07, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss the...

Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene — Oct 2nd, 2024

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass., October 02, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in Eur...